emapticap pegol (NOX E36) - Noxxon
BioEurope Spring Conference (Noxxon) - Mar 15, 2011 - Spiegelmer (NOX-E36) / Noxxon; Initiation of P2a trial in diabetic nephropathy Q4'11; Anticipated P1b study completion in diabetics; Anticipated renal impairment study completion in Q3 '11 
Anticipated P1b study completion • Anticipated P2 enrollment Renal Disease
http://www.larvolonline.com/tlg/ccdb/NoxxonBioeuropespringconferenceMar15.pdf
 
Mar 15, 2011
 
 
ec56f21f-113d-4ca8-abad-08731a84703b.png